Patients with extensive ulcerative colitis for 10 years or more carry an increased risk of developing colorectal cancer.' -4 Early reports suggested that these patients had a poor prognosis. None of the 20 cases of colorectal cancer complicating ulcerative colitis reported by Bargen from the Mayo Clinic survived five years, 12 of them dying in the early postoperative period.5 Two further studies from the same centre reported a five year survival of 3%. 6 7 In 1959 Slaney and Brooke calculated a five year survival of 18-6% from an analysis of all cases of colorectal cancer reported in the literature.8 This was a selected analysis as only 112 of the 468 cancers reported included sufficient data for estimating the five year survival.
Recent reports using the method of matched controls suggest that the five year survival from colorectal cancer complicating ulcerative colitis is of the order of 40% and not significantly different from the outcome of colorectal cancer arising de novo in the general population.9-11 In these analyses ulcerative colitis patients developing colorectal cancer were matched for age, sex, site of disease, and Dukes' staging with non-colitic cancer controls (Table 1 ).
An even better survival was reported by Ritchie for colorectal cancer in both colitic and non-colitic groups. 12 The control population used were patients with colorectal cancer but no evidence of colitis presenting at St Mark's Hospital over the same period as the ulcerative colitis patients with colorectal cancer (Table 1) .
Hulten and his colleagues showed a poor survival in both colitic and non-colitic cancers in an analysis confined to patients developing cancer before 40 years of age. 3 The poor outlook with 12% five year survival in colitic cancers and 25% in controls of non-colitic cancers is surprising. In a large selected series of 951 such young patients developing colorectal cancer below 40 years of age the crude five year survival was 32%, which is similar to the survival reported from colorectal cancer in the general population. '4 In this study we The actuarial five year survival was 33.5 % (95% confidence limits 16.9-50.1%).
The comparable figure for the general population at five years was 32.6% (95% confidence limits 28-2-37 0%) ( Table 2 ).
The percentage survival with time of patients with colorectal cancer complicating ulcerative colitis compared with the general population is shown in Figure 2 .
The five year survival rate between cases and controls was not significantly different (33.5% and 32-6% respectively).
DUKES' CLASSIFICATION
There was sufficient histological evidence to establish the Dukes' classification in 22 of the 35 cancers. Three cancers were multicentric in origin and were excluded from the Dukes' classification. Of the remaining 19 cancers four were Dukes' A, five Dukes' B, three Dukes' C, and seven had distant metastases. The proportion of Dukes' A lesions was higher in the colorectal cancers detected unexpectedly and their survival much better than that observed in the interval cancers detected during the period of follow up. The degree of histological differentiation was asssessed in 27 colorectal cancer. Four were well differentiated (15%), nine moderately well differentiated (33%), and 14 poorly differentiated (52%). It is difficult to assess the effect on survival of the increased incidence of multiple cancers in the ulcerative colitic group as most authors exclude such patients from their analysis of survival. The incidence of multiple cancers in patients with ulcerative colitis varies from 4-26% in reported series ( Table 1) . The proportion of patients with multiple cancers in this series was 11.4% whereas the incidence of multiple cancers for non-colitic cancers was 2-35%. 12 14 Presumably the survival of patients with multiple synchronous cancers will be determined by the Dukes' staging of the most advanced lesion at the time of diagnosis.
The survival among patients with colorectal cancer complicating colitis and those with noncolitic cancers from the general population will depend on the proportions of Dukes' A, B, C, and distant metastases present at the time of diagnosis in each group. The observation that the survival curves in the two groups are similar (Fig. 2) in our series suggests that the proportion of Dukes' A, B, C, and distant metastases at diagnosis was the same in the ulcerative colitis patients as in the general population. Certainly in other series the proportion of patients presenting with distant metastases at diagnosis in colitic and non-colitic colorectal cancer is around 30% for the colitic group and 25% for the general population'2 14 (Table 1) . This study and earlier reports in the literature suggest that colorectal cancer complicating ulcerative colitis are not yet being diagnosed any earlier than in the population at large. This is surprising as patients with ulcerative colitis are usually under regular review and many cancers are diagnosed incidentally on histological examination of resected specimens at panproctocolectomy for symptomatic colitis (Table 1 ). In our analysis all but one of the patients found to have colorectal cancer incidentally at panproctocolectomy for symptomatic colitis survived for more than 12 years. Colorectal cancers diagnosed incidentally at surgery, however, are not always early lesions. Lavery"1 reported 19 such cancers of which six were carcinoma in situ, five Dukes' A, six Dukes' B, and two Dukes' C lesions.
Certain factors militate against early diagnosis of cancer in ulcerative colitis, however. For example, patients with extensive colitis may become asymptomatic and are lost to follow up, only to return many years later with symptomatic cancer. Some patients have only mild colitic symptoms and are only seen in hospital for the first time with colorectal cancer. Finally, the symptoms of colorectal cancer -for example, rectal bleeding -may not occasion alarm in colitic patients whereas such symptoms would alert the individual experiencing them for the first time to seek medical advice.
There is a small subgroup of patients with extensive disease of longstanding in any series of ulcerative colitis patients who are particularly at risk of developing colorectal cancer and must be considered either for careful monitoring or elective panproctocolectomy especially if their colitis started when they were young. 4 
